Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;177(8):1279-1292.
doi: 10.1007/s00431-018-3182-2. Epub 2018 Jun 8.

Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases

Xuan Li  1 , Ye Chen  1 , Yunjia Tang  1 , Yueyue Ding  1 , Qiuqin Xu  1 , Lin Sun  1 , Weiguo Qian  1 , Guanghui Qian  2 , Liqiang Qin  3 , Haitao Lv  4
Affiliations
Review

Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases

Xuan Li et al. Eur J Pediatr. 2018 Aug.

Abstract

The purpose of this study was to identify the clinical features and laboratory factors that are predictive of intravenous immunoglobulin (IVIG)-resistant Kawasaki disease. Multiple databases were searched for relevant studies on IVIG-resistant Kawasaki disease published from January 2002 to April 2017. Eligible studies were retrieved by manual review of the references. Stata 12 was used for the meta-analysis. Weighted mean differences and odds ratios with 95% confidence intervals were calculated for several indices. Twenty-eight studies involving 26,260 patients comprising 4442 IVIG-resistant Kawasaki disease patients and 21,818 IVIG-sensitive Kawasaki disease patients were included. The meta-analysis showed that the erythrocyte sedimentation rate (ESR) in the IVIG-resistant group was significantly higher than that in the IVIG-sensitive group, and that platelet count and hemoglobin levels were significantly lower in the IVIG-resistant group. The patients with oral mucosa alterations, cervical lymphadenopathy, swelling of the extremities, polymorphous rash, and initial administration of IVIG ≤ 4.0 days after the onset of symptoms were more likely to be IVIG resistant.

Conclusion: The initial administration of IVIG ≤ 4.0 days after the onset of symptoms increased ESR and decreased hemoglobin and platelet counts, oral mucosa alterations, cervical lymphadenopathy, swelling of the extremities, and polymorphous rash and are the risk factors for IVIG-resistant Kawasaki disease. What is Known: • Recent reports on this topic are about aspartate aminotransferase (AST), alanine aminotransferase (ALT), gammaglutamyl transferase, total bilirubin, white blood cells, platelets, erythrocyte sedimentation rate (ESR), polymorphonuclear leukocytes (PMN), C-reactive protein (CRP), pro-brain natriuretic peptide (BNP), albumin, and sodium as the risk factors in the IVIG-resistant Kawasaki disease; however, no studies have been published on clinical features as predictors of IVIG resistance. What is New: • This meta-analysis identified the clinical features, the initial administration of IVIG ≤ 4.0 days after the onset of symptoms, and much more comprehensive laboratory indicators, such as hemoglobin, as predictors of IVIG-resistant Kawasaki disease.

Keywords: Intravenous immunoglobulin; Kawasaki disease; Meta-analysis; Risk.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflicts of interest.

Informed consent

None.

Figures

Fig. 1
Fig. 1
Literature selection for the meta-analysis
Fig. 2
Fig. 2
Prevalence of intravenous immunoglobulin (IVIG)-resistant Kawasaki disease among patients who received IVIG treatment ≤ 4.0 days after the onset of symptoms
Fig. 3
Fig. 3
Hemoglobin as a predictive index for resistance to intravenous immunoglobulin therapy in Kawasaki disease
Fig. 4
Fig. 4
Platelet count as a predictive index for intravenous immunoglobulin resistance in Kawasaki disease
Fig. 5
Fig. 5
Erythrocyte sedimentation rate (ESR) as a predictive index for intravenous immunoglobulin resistance in Kawasaki disease
Fig. 6
Fig. 6
Changes in oral mucosa as a predictive index for intravenous immunoglobulin resistance in Kawasaki disease
Fig. 7
Fig. 7
Conjunctival congestion as a predictive index for intravenous immunoglobulin resistance in Kawasaki disease
Fig. 8
Fig. 8
Cervical lymphadenopathy as a predictive index for intravenous immunoglobulin resistance in Kawasaki disease
Fig. 9
Fig. 9
Swelling of the extremities as a predictive index for intravenous immunoglobulin resistance in Kawasaki disease
Fig. 10
Fig. 10
Polymorphous rash as a predictive index for intravenous immunoglobulin resistance in Kawasaki disease
See this image and copyright information in PMC

References

    1. Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr. 2008;153(3):365–368. doi: 10.1016/j.jpeds.2008.03.014. - DOI - PubMed
    1. Baek JY, Song MS. Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. Korean J Pediatr. 2016;59(2):80–90. doi: 10.3345/kjp.2016.59.2.80. - DOI - PMC - PubMed
    1. Campbell AJ, Burns JC. Adjunctive therapies for Kawasaki disease. J Inf Secur. 2016;72(Suppl):S1–S5. - PubMed
    1. Cha S, Yoon M, Ahn Y, Han M, Yoon KL. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease. J Korean Med Sci. 2008;23(4):718–722. doi: 10.3346/jkms.2008.23.4.718. - DOI - PMC - PubMed
    1. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013;99(2):76–82. doi: 10.1136/heartjnl-2012-302126. - DOI - PubMed

MeSH terms

Substances